These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 26798188)
21. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. Mizutani Y; Yoshida O; Ukimura O; Kawauchi A; Bonavida B; Miki T Cancer Biother Radiopharm; 2002 Oct; 17(5):563-7. PubMed ID: 12470426 [TBL] [Abstract][Full Text] [Related]
22. Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder. Miyake M; Fujimoto K; Anai S; Ohnishi S; Kuwada M; Nakai Y; Inoue T; Matsumura Y; Tomioka A; Ikeda T; Tanaka N; Hirao Y Oncol Rep; 2011 Mar; 25(3):653-60. PubMed ID: 21206978 [TBL] [Abstract][Full Text] [Related]
23. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage. Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643 [TBL] [Abstract][Full Text] [Related]
24. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder. Liu L; Zhu D; Gao R; Guo H Urol Int; 2008; 81(1):72-6. PubMed ID: 18645275 [TBL] [Abstract][Full Text] [Related]
25. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Kopparapu PK; Boorjian SA; Robinson BD; Downes M; Gudas LJ; Mongan NP; Persson JL Anticancer Res; 2013 Jun; 33(6):2381-90. PubMed ID: 23749886 [TBL] [Abstract][Full Text] [Related]
26. Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma. Yang S; Wu X; Luo C; Pan C; Pu J World J Urol; 2010 Aug; 28(4):473-8. PubMed ID: 20593288 [TBL] [Abstract][Full Text] [Related]
28. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 30 pure and mixed cases. Wasco MJ; Daignault S; Bradley D; Shah RB Hum Pathol; 2010 Feb; 41(2):163-71. PubMed ID: 19800100 [TBL] [Abstract][Full Text] [Related]
29. Clinical significance of the reduction of UT-B expression in urothelial carcinoma of the bladder. Li C; Xue H; Lei Y; Zhu J; Yang B; Gai X Pathol Res Pract; 2014 Dec; 210(12):799-803. PubMed ID: 25445116 [TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical determination of ETS-1 oncoprotein expression in urothelial carcinomas of the urinary bladder. Sari A; Calli A; Gorgel SN; Altinboga AA; Kara C; Dincel C; Cakalagaoglu F Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):153-8. PubMed ID: 21623185 [TBL] [Abstract][Full Text] [Related]
32. Expression of Phospho-ELK1 and Its Prognostic Significance in Urothelial Carcinoma of the Upper Urinary Tract. Inoue S; Ide H; Fujita K; Mizushima T; Jiang G; Kawahara T; Yamaguchi S; Fushimi H; Nonomura N; Miyamoto H Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29518027 [TBL] [Abstract][Full Text] [Related]
33. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. Miyamoto H; Yao JL; Chaux A; Zheng Y; Hsu I; Izumi K; Chang C; Messing EM; Netto GJ; Yeh S BJU Int; 2012 Jun; 109(11):1716-26. PubMed ID: 22221549 [TBL] [Abstract][Full Text] [Related]
34. The Clinical Study of Urokinase-Type Plasminogen Activator and Vascular Endothelial Growth Factor in Gastric Cancer. Yang XW; Gao F; Chen YJ; Teng FM Cell Biochem Biophys; 2015 Jul; 72(3):649-52. PubMed ID: 27352182 [TBL] [Abstract][Full Text] [Related]
35. [Expression of VEGF and tumor angiogenesis in bladder cancer]. Wang S; Xia T; Zhang Z; Kong X; Zeng L; Mi P; Xue Z Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):34-6. PubMed ID: 11831983 [TBL] [Abstract][Full Text] [Related]
36. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Korkolopoulou P; Goudopoulou A; Voutsinas G; Thomas-Tsagli E; Kapralos P; Patsouris E; Saetta AA Urology; 2004 Jun; 63(6):1198-204. PubMed ID: 15183989 [TBL] [Abstract][Full Text] [Related]
37. Overexpression of annexin 1 in the development and differentiation of urothelial carcinoma. Kang WY; Chen WT; Huang YC; Su YC; Chai CY Kaohsiung J Med Sci; 2012 Mar; 28(3):145-50. PubMed ID: 22385607 [TBL] [Abstract][Full Text] [Related]
38. Expression and predictive value of lymph-specific markers in urothelial carcinoma of the bladder. von Hardenberg J; Martini T; Knauer A; Ströbel P; Becker A; Herrmann E; Schubert C; Steidler A; Bolenz C Urol Oncol; 2014 Jan; 32(1):54.e9-17. PubMed ID: 24360666 [TBL] [Abstract][Full Text] [Related]
39. [Molecular markers for the diagnosis of non-muscle-invasive bladder cancer]. Glybchenko PV; Shakhpazian NK; Ponukalin AN; Zakharova NB Klin Lab Diagn; 2011 May; (5):16-20. PubMed ID: 21789798 [TBL] [Abstract][Full Text] [Related]
40. Tumorous CD10 Is More Strongly Related to the Progression of Urothelial Carcinoma than Stromal CD10. Kumagai-Togashi A; Uozaki H; Kikuchi Y; Watabe S; Numakura S; Watanabe M Anticancer Res; 2019 Feb; 39(2):635-640. PubMed ID: 30711939 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]